Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Bridget P KeenanDepartment of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-6075-489X
Guilin QiaoDepartment of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-8615-3467
Nicholas KundaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.ORCID 0009-0000-1558-6559
Lyonell KoneDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.
Sophia M GuldbergDepartments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-0102-4341
Letizia TodeschiniDepartment of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0009-0008-3134-9228
Prabhakaran KumarDepartment of Microbiology & Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.ORCID 0000-0002-0657-6938
Tommaso PolliniDepartment of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-8036-5699
Sophia HernandezDepartment of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-5763-2672
Jianzhong QinDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.
Lawrence FongDepartment of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-6428-428X
Matthew H SpitzerDepartments of Otolaryngology-Head and Neck Surgery and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5291-3819
Bellur S PrabhakarDepartment of Microbiology & Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.ORCID 0000-0001-9815-9850
Ajay V MakerDepartment of Surgery, Division of Surgical Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-8234-2762
Funding
Strengthening Stakeholder Engagement in Human Research Protections.UL1TR002003 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARNIK, NIRANJAN SUBHASH, MERMELSTEIN, ROBIN J. · 2016 to 2024
$33.7M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6M
Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer MetastasesR37CA238435 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ajay V. Maker · 2020 to 2026
$2.5M
Enhancing anti-tumor immune responses in colon cancer metastasesK08CA190855 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MAKER, AJAY V. · 2014 to 2018
Colorectal cancer and liver metastases are a leading cause of cancer-related mortality. Overexpression of the immunostimulatory cytokine TNFSF14/LIGHT associates with improved survival and correlates with increased tumor-infiltrating lymphocytes in patients and a clinically relevant model of colorectal liver metastases. We demonstrate that LIGHT monotherapy activates T cells, but also induces T cell exhaustion and the recruitment of immunosuppressive elements. As colorectal liver metastases exhibit high levels of CTLA-4 expression, we combined LIGHT overexpression with anti-CTLA-4, leading to complete tumor control. The combination functions by homing tumor-infiltrating lymphocytes, inducing tumor antigen-specific T cells, and reversing T cell exhaustion. Whereas both LIGHT overexpression and anti-CTLA-4 increase tumor-promoting macrophages, the combination eliminates this population. The ability of LIGHT overexpression combined with CTLA-4 inhibition to reverse T cell exhaustion and myeloid cell suppression is supported by analysis of complementary patient cohorts and has strong clinical relevance, especially given that liver metastases contribute to immunotherapy resistance across various cancer types.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases. · full record | OpenQuestion